The guidelines allow for the addition of short-term clopidogrel to an oral anticoagulant (OAC) in patients with an established OAC indication, such as atrial fibrillation (AF), who undergo transcatheter aortic valve replacement (TAVR). But does the extra antithrombotic protection come with safety issues? Continue reading →

Anatomic severity of diseasebut not severity of ischemiapredicted the risk of death or MI over 4 years of follow-up in the ISCHEMIA trial, a new analysis shows. However, an invasive strategy as compared with medical therapy offered no benefit regardless of disease severity based on level of ischemia or extent of coronary disease, according to ISCHEMIA investigators. Continue reading →

William R Hiatt More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence of clear benefit, clopidogrel exposure along with aspirin and rivaroxaban should be minimised or avoided to reduce this risk, concluded William R Hiatt (University of Colorado Anschutz School of Medicine, Aurora, USA), presenting a subgroup analysis of the VOYAGER-PAD trial during the American College of Cardiology/World Congress of Cardiologys virtual scientific sessions (ACC.20/WCC Virtual)originally scheduled to take place on 2830 March in Chicago, USA Continue reading →

CYBERSPACE Online learning rises to the next level starting March 28 with the ambitious, pioneering response from the American College of Cardiology (ACC) to the cancellation of its annual scientific sessions live meeting forced by the COVID-19 pandemic, uncharted territory in most every way. The sessions are going online in three simultaneous real-time streams and videos and slides on demand, archived for 30-day access. And it will be free to literally anyone with internet and a computer, tablet, or smartphone Continue reading →